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Isoniazid resistance levels of 
Mycobacterium tuberculosis can 
largely be predicted by high-
confidence resistance-conferring 
mutations
Pauline Lempens1,2, Conor J. Meehan1, Koen Vandelannoote1, Kristina Fissette1, Pim de Rijk1, 
Armand Van Deun1, Leen Rigouts1,2 & Bouke C. de Jong1
The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG. 
Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below 
the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still remain 
partly active in presence of a katG mutation. We therefore investigated which genetic mutations 
predict the level of phenotypic isoniazid resistance in clinical M. tuberculosis isolates. To this end, the 
association between known and unknown isoniazid resistance-conferring mutations in whole genome 
sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level 
resistance characterized by a mode of 6.4 mg/L for the very common katG Ser315Thr mutation, and 
always very high MICs (≥19.2 mg/L) for the combination of katG Ser315Thr and inhA c-15t. Contrary 
to common belief, isolates harbouring inhA c-15t alone, partly also showed moderate-level resistance, 
particularly when combined with inhA Ser94Ala. No overt association between low-confidence or 
unknown mutations, except in katG, and isoniazid resistance (level) was found. Except for the rare katG 
deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a 
single mutation in katG or inhA.
Effective control of tuberculosis (TB) is especially complicated among patients with multidrug-resistant TB 
(MDR-TB), which is characterized by resistance to at least isoniazid and rifampicin, the two most powerful 
drugs against TB, used in standard first-line treatment1,2. Preventing the activation of the pro-drug isoniazid, 
mutations in katG are the most frequent cause of isoniazid resistance3,4. Although more than 300 different katG 
mutations have been identified, mutations at codon 315 of the gene are most prevalent, with, on average, 64% of 
isoniazid-resistant clinical isolates worldwide carrying a katG 315 mutation3,4. Moreover, one particular amino 
acid substitution (serine to threonine) accounts for 95% of all katG 315 mutations4. Mutations in katG are associ-
ated with a wide range of moderate- to high-level isoniazid resistance, above the commonly tested concentrations 
of 0.2 and 1 mg/L in solid- and 0.1 and 0.4 mg/L in liquid medium5. The katG Ser315Thr mutation in particular is 
associated with minimum inhibitory concentrations (MICs) ranging from 2 to >10 mg/L5, while (partial) dele-
tion of the katG gene causes very high MICs (>25.6 mg/L)6,7.
In addition to katG mutations, isoniazid resistance arises from mutations in the promoter region of inhA, 
which lead to overexpression of isoniazid’s target InhA, requiring higher doses of the drug to achieve complete 
inhibition3. Mutations in the promoter region of inhA tend to result in low-level phenotypic resistance5 and also 
confer resistance to the second-line drugs ethionamide and prothionamide3. The most prevalent inhA promoter 
region mutation is the c-15t mutation, which is present in, on average, 19% of isoniazid-resistant clinical isolates 
worldwide4. In addition to the two most frequent causes of isoniazid resistance, mutations in katG expression reg-
ulatory genes (e.g. the furA-katG intergenic region and sigI) and in the coding region of inhA, as well as mutations 
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involving isoniazid inactivation, redox potential alteration, mycothiol biosynthesis alteration and drug excretion 
by efflux pumps, have been described3.
Combinations of mutations in katG and the inhA promoter region confer high-level resistance 
(MICs > 10 mg/L)8. However, these variations do not explain the entire phenotypic heterogeneity observed for 
katG mutations. We therefore hypothesized that other (combinations of) genetic mutations contribute to the wide 
range of MICs observed among isoniazid-resistant isolates of Mycobacterium tuberculosis.
The therapeutic range of isoniazid is 3–6 mg/L9, typically achieved with a normal 300 mg dose for patients with 
a body weight >50 kg10, although serum levels can vary11 due to multiple factors, including a fatty meal, leading to 
lower peaks9, and the patient’s acetylator status12. Whereas treatment with isoniazid is often ceased when isonia-
zid resistance has been demonstrated at the 0.2 mg/L (solid medium) or 0.1 mg/L (liquid medium) cut-off, there is 
evidence that for low- to moderate-level resistance, isoniazid can have some remaining effectiveness at normal or 
elevated doses5,13–18. Recent WHO guidelines for the treatment of MDR-TB recommend the 9-month ‘Bangladesh 
regimen’, which includes a double dose of isoniazid (600 mg, rather than 300 mg)19,20.
Whereas conventional drug susceptibility testing takes days to weeks due to the slow growth rate of M. tuber-
culosis, novel molecular tests are able to analyse multiple genes simultaneously and provide the results within 
hours to days. The widely used commercial line probe assays (LPAs) for the detection of resistance to rifampicin 
and isoniazid are commonly thought to indicate high-level resistance to isoniazid if a katG mutation is detected, 
rendering the drug useless21. To shed some light on the highly variable MICs, even for the same katG mutation, 
we investigated which (combinations of) genetic mutations predict the level of phenotypic isoniazid resistance in 
clinical M. tuberculosis isolates. Incorporating this genetic information in rapid molecular tests would facilitate 
optimized use of isoniazid, one of the most potent anti-TB drugs, thereby enhancing effective and safe treatment 
of drug-resistant TB.
Methods
Ethics. Ethical approval for the Bangladesh treatment regimen and research methods was obtained from the 
Bangladesh Medical Research Council, Dhaka, Bangladesh15. Before enrolment, each patient completed and 
signed an informed consent form in the local language15. Ethical approval for this sub-study on the M. tuber-
culosis isolates was obtained from the ITM Institutional Review Board (IRB/AB/ac/125) and the analyses were 
performed in an ISO 15189 accredited environment.
M. tuberculosis datasets. Two sets of M. tuberculosis isolates were selected for the present study 
(Supplementary Fig. S1). The first set includes 129 well-characterized strains from the WHO/TDR-TB Strain 
Bank (hereafter referred to as WHO-TDR strains) whose whole genomes had been sequenced on an Illumina 
HiSeq (ENA Short Read Archive accession PRJEB11653)22. The WHO/TDR-TB Strain Bank holds strains of 
diverse geographical origin with diverse resistance profiles to first- and second-line drugs (Supplementary 
Table S1)23. In addition to these 129 strains, four other WHO-TDR strains had whole genome sequences available 
yet were excluded, three due to heteroresistance as they were found to have a mutation in katG in 21%, 29% and 
43% of reads (using PhyResSE, see below) and one because a mixture of resistant as well as susceptible bacilli 
for multiple drugs was suggestive of mixed infection. Isoniazid MIC determination on Löwenstein-Jensen (LJ) 
medium using concentrations of 0.05, 0.2, 0.8, 1.6 and 3.2 mg/L had been carried out previously for all 129 strains 
using the same method as described below23. These MIC values were included in this study. WHO-TDR strains 
having an isoniazid MIC ≥1.6 mg/L (n = 61) were selected for further isoniazid MIC determination in this study 
using higher drug concentrations.
The second set comprised isolates derived from baseline samples of MDR-TB patients from the Bangladesh 
cohort15,16. Patients were treated with a double dose isoniazid (7–12 mg/kg) as part of a 7-drug standardized 
MDR-TB regimen15,16. Only isolates that were highly resistant to fluoroquinolones (gatifloxacin MIC >1 mg/L 
on LJ) (n = 49) were included in order to enrich the panel with patients with an extensive TB treatment history 
resulting in highly isoniazid-resistant isolates. One isolate was excluded since it was no longer viable. Isoniazid 
MIC determination and whole genome sequencing (WGS) were carried out on the remaining 48 isolates. 
Subsequently, another isolate was excluded because it was found to have a mutation in the inhA promoter region 
in 48% of reads, suggesting isoniazid heteroresistance. As a result, 47 isolates were included in the analysis.
Phenotypic drug susceptibility testing. Isoniazid MIC (MIC99, defined as the lowest drug concentra-
tion that inhibits 99% of visible bacillary growth) was determined for 61 WHO-TDR strains and 48 Bangladesh 
isolates on LJ medium using concentrations of 1.6, 3.2, 6.4, 12.8, 19.2 and 25.6 mg/L24. H37Rv (BCCM/
ITM083715) and an MDR strain (BCCM/ITM021617) routinely used for quality control of in-house prepared 
media were run in tandem as a negative and positive control, respectively. MDR was defined as concurrent resist-
ance to isoniazid and rifampicin, and non-MDR as resistance to isoniazid or rifampicin, but not both, or sus-
ceptibility to both. MICs were classified into four resistance groups, i.e. susceptible (MIC ≤ 0.2 mg/L), low-level 
resistant (0.8 ≤ MIC ≤ 1.6 mg/L, i.e. MICs larger than or equal to 0.8 mg/L but smaller than or equal to 1.6 mg/L), 
moderate-level resistant (3.2 ≤ MIC ≤ 12.8 mg/L, i.e. MICs larger than or equal to 3.2 mg/L but smaller than or 
equal to 12.8 mg/L) and high-level resistant (MIC ≥ 19.2 mg/L). Due to a lack of data in the literature on high 
isoniazid MIC frequencies and in particular their clinical relevance5–8, the border between moderate-level and 
high-level resistance was defined arbitrarily, based on the frequency distributions observed in this study. The 
groups were used in all subsequent analyses.
gDNA extraction and whole genome sequencing. Whereas WGS data were already available for the 
WHO-TDR strains22, genomic DNA (gDNA) extraction and WGS were carried out for 48 Bangladesh isolates 
(NCBI Sequence Read Archive, BioProject accession PRJNA343956). To this end, colonies from LJ medium were 
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heat-killed in 150 µL 0.5 M Tris-EDTA buffer. To each sample, 150 µL 30% sucrose solution, 50 µL 100 mg/mL 
lysozyme (Sigma-Aldrich, St. Louis, USA) and 20 µL 10 mg/mL RNase A (Life Technologies, Carlsbad, USA) were 
added, followed by shaking (200 rpm) at 37 °C for one hour. Subsequently, 100 µL 20% SDS, 40 µL 2.5 mg/mL pro-
teinase K (MP Biomedicals, Santa Ana, USA) and approximately 50 µL glass beads (150–212 μm, Sigma-Aldrich, 
St. Louis, USA) were added to each sample, followed by shaking (200 rpm) at 37 °C overnight. Samples were 
then heated at 70 °C for 5 minutes and agitated using the FastPrep-24 (MP Biomedicals, Santa Ana, USA) at 
speed 5.0 for two times 25 seconds, followed by centrifugation. The Maxwell 16 Cell DNA Purification Kit 
(Promega, Madison, USA) was used to purify the extracted gDNA according to the manufacturer’s instructions. 
Fragmentation and purity were examined through gel electrophoresis and yield was measured using the Qubit 
dsDNA BR Assay Kit (Life Technologies, Carlsbad, USA) according to the manufacturer’s instructions. Extracted 
gDNA was sequenced (next generation sequencing) on an Illumina MiSeq platform using the Illumina Nextera 
XT DNA Library Preparation Kit.
Genotypic-phenotypic correlation. To check for genetic mutations (primarily single-nucleotide poly-
morphisms (SNPs)) known to confer resistance to isoniazid, Illumina reads were uploaded to an online tool 
called Phylo-Resistance Search Engine (PhyResSE) between July and October 201525. After the removal of low 
quality reads based upon their Quality score (Q < 20), PhyResSE maps the reads against the M. tuberculosis 
H37Rv reference genome (GenBank ID: NC_000962.3)26,27 and pre-processes the results. Subsequently, variants 
are determined and compared with a list of resistance-conferring and lineage-specific mutations25. This list is 
based on well-known mutations collected from the literature supplemented by the author’s in-house data and is 
regularly updated (during the study period no isoniazid resistance-conferring mutations were added)25. In addi-
tion, mutations for which strong experimental evidence exists are distinguished as high-confidence mutations25.
In order to search for all SNPs and insertions/deletions (indels) outside of well-known drug resistance-related 
positions of the genome, whole genome sequences were assembled from the reads of the final set of 129 
WHO-TDR strains and 47 Bangladesh isolates with the Snippy software (version 3.0)28. Snippy compares reads to 
the M. tuberculosis H37Rv reference genome (NC_000962.3)26,27, employing the variant caller FreeBayes (version 
0.9.21–7-g7dd41db)29. SNPs and indels found by Snippy were analysed in two ways. First, they were searched 
for low-confidence mutations. Included were all previously described isoniazid resistance-conferring mutations 
reviewed by Vilchèze and Jacobs3 and TBDReaMDB30, as well as any other non-synonymous mutations in the 
genes in which these previously described mutations were found. Second, to search for unknown (combinations 
of) resistance-conferring mutations, SNPs and indels were analysed using PICA (version 1.0.1) for each M. tuber-
culosis dataset separately31. PICA comprises a genotype-phenotype association rule method that searches for 
combinations of mutations that are characteristic of a certain phenotype (i.e. resistance level in this study)31. In 
order to search for (combinations of) genes associated with resistance, as opposed to individual mutations, PICA 
was also applied on SNPs and indels grouped by gene. Association rules found by PICA having a LaPlace associ-
ation measure >0.95 were considered to be reliable.
Subsequently, a SNP alignment was made from the Snippy output for each dataset using an in-house Python 
script. Based on this SNP alignment, a maximum likelihood tree was built using Randomized Axelerated 
Maximum Likelihood (RAxML) (version 8.2.4)32 with Stamatakis ascertainment bias correction33,34 and a 
GTR + CAT model of evolution. The distribution of drug resistance-related mutations was correlated with the 
different phylogenetic lineages using the online interactive Tree Of Life (iTOL) tool35.
Analysis. To test whether the presence of a (combination of) high-confidence mutation(s) was significantly 
associated with the isoniazid resistance level, Pearson’s chi-squared tests (α = 0.01 (rather than α = 0.05, to cor-
rect for multiple comparisons) were carried out for mutations found in more than two strains in the same dataset 
(IBM SPSS Statistics 23). For the WHO-TDR strains, the relative frequencies of these mutations found in each 
of the isoniazid-resistant groups (low-, moderate- and high-level) were compared to the relative frequencies in 
the susceptible group (groups as described below). For the Bangladesh isolates, the relative frequencies of the 
mutations found were compared between the moderate- and high-level resistant groups, since these isolates were 
all moderate- to high-level resistant. For low-confidence mutations, Pearson’s chi-squared tests (α = 0.01 (rather 
than α = 0.05, to correct for multiple comparisons) were carried out to test whether these mutations, grouped 
by gene, were significantly associated with the isoniazid resistance level. WHO-TDR and Bangladesh data were 
pooled.
Data availability. Isoniazid MICs as well as high- and low-confidence mutations are available in this article 
and its Supplementary Information file. WGS reads are available in the ENA SRA (WHO-TDR strains, https://
www.ebi.ac.uk/ena/data/view/PRJEB11653) and the NCBI SRA (Bangladesh isolates, https://www.ncbi.nlm.nih.
gov/bioproject/PRJNA343956/). In addition, Bangladesh WGS reads and associated genotypic and phenotypic 
data have been submitted to the Relational Sequencing TB Data Platform (ReSeqTB) and will be publicly available 
upon publication of this article.
Results
Phenotypic resistance to isoniazid. Isoniazid-resistant isolates (MIC > 0.2 mg/L, based on the propor-
tion method cut-off for isoniazid5) were characterized by a mode of 6.4 mg/L and a second, smaller peak repre-
senting MICs ≥25.6 mg/L (Fig. 1). The Bangladesh MDR isolates (n = 47) tended to have a higher isoniazid MIC 
than the WHO-TDR MDR strains (n = 48), although their mode and median were the same (both 6.4 mg/L) 
(Bangladesh MDR versus WHO-TDR MDR, Fig. 1). The WHO-TDR collection included 58 isoniazid-susceptible 
strains.
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Association between high-confidence mutations and phenotypic resistance level. 
High-confidence mutations, alone or in combination, were detected in 65/71 phenotypically isoniazid-resistant 
WHO-TDR strains and 45/47 Bangladesh isolates, while 1 of the 58 susceptible isolates had a mutation in inhA 
(Table 1 and Supplementary Tables S1 and S2). Among these high-confidence mutations, the katG Ser315Thr 
mutation alone (for WHO-TDR in 43/66 and for Bangladesh in 35/45 isolates with any high-confidence 
mutation), the inhA promoter region c-15t mutation alone (WHO-TDR 10/66) and the combination of both 
(WHO-TDR 5/66 and Bangladesh 7/45) were observed most frequently. For both the WHO-TDR strains (Fig. 2a) 
and the Bangladesh isolates (Fig. 2b), the high-confidence mutations were widely spread across the different phy-
logenetic lineages, consistent with the known convergent evolution of isoniazid resistance mutations36. The inhA 
Figure 1. Relative frequency distributions of the isoniazid MICs of the WHO-TDR and Bangladesh isolates. 
MICs are depicted separately for MDR (i.e. concurrently resistant to isoniazid and rifampicin) and non-MDR 
isolates (i.e. resistant to isoniazid or rifampicin, but not both, or susceptible to both), given the assumption that 
cumulative drug exposure, including to isoniazid, would have been higher for most MDR patients. WHO-TDR 
strains with an MIC up to and including 0.8 mg/L had this MIC determined previously. All other MICs were 
determined in this study, i.e. 1.6 mg/L was the lowest concentration used in this study. MDR = multidrug-
resistant; MIC = minimum inhibitory concentration.
susceptible low-level resistance moderate-level resistance high-level resistance
n % n % n % n %
a WHO-TDR
wild type 57 98.3% 5 35.7% 1 1.9% 0 0.0%
katG Ser315Thr alone 0 0.0% 0 0.0% 43 82.7% (p =0. 000) 0 0.0%
katG Ser315Asn alone 0 0.0% 2 14.3% (p = 0.004) 2 3.8% 0 0.0%
inhA promoter region c-15t alone 0 0.0% 7 50.0% (p = 0.000) 3 5.8% 0 0.0%
inhA Ser94Ala alone 1 1.7% 0 0.0% 0 0.0% 0 0.0%
katG Ser315Thr + inhA promoter 
region c-15t 0 0.0% 0 0.0% 0 0.0% 5 100% (p = 0.000)
inhA promoter region c-15t + inhA 
Ser94Ala 0 0.0% 0 0.0% 2 3.8% 0 0.0%
inhA promoter region c-15t + inhA 
Ile194Thr 0 0.0% 0 0.0% 1 1.9% 0 0.0%
total 58 100% 14 100% 52 100% 5 100%
b Bangladesh
wild type 1 2.8% 1 9.1%
katG Ser315Thr alone 34 94.4% (p = 0.000) 1 9.1%
inhA Ser94Ala alone 1 2.8% 0 0.0%
katG Ser315Thr + inhA promoter region c-15t 0 0.0% 7 63.6% (p = 0.000)
katG Ser315Gly + inhA promoter region c-15t + inhA Ile194Thr 0 0.0% 1 9.1%
inhA promoter region c-15t + inhA Ser94Ala 0 0.0% 1 9.1%
Total 36 100% 11 100%
Table 1. (Combinations of) high-confidence mutations detected in the WHO-TDR (a) and Bangladesh (b) 
isolates. susceptible: MIC ≤ 0.2 mg/L; low-level resistance: 0.8 ≤ MIC ≤ 1.6 mg/L; moderate-level resistance: 
3.2 ≤ MIC ≤ 12.8 mg/L; high-level resistance: MIC ≥ 19.2 mg/L.
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promoter region c-15t mutation alone was present significantly more often in the low-level resistant group com-
pared to the susceptible group, but not in the moderate- and high-level resistant groups (WHO-TDR, p = 0.001). 
Similarly, the katG Ser315Thr mutation alone was present significantly more often in the moderate-level resistant 
group compared to the susceptible group (WHO-TDR, p = 0.001) or the high-level resistant group (Bangladesh, 
p = 0.001). Lastly, the combination of the katG Ser315Thr mutation with the c-15t mutation in the inhA promoter 
region was present exclusively and significantly more often in the high-level resistant group compared to the sus-
ceptible group (WHO-TDR, p = 0.001) or the moderate-level resistant group (Bangladesh, p = 0.001). Isoniazid 
MIC relative frequency distributions of isolates harbouring the inhA promoter region c-15t mutation alone, the 
katG Ser315Thr mutation alone, the combination of these two mutations, or no high-confidence mutation for 
isoniazid (wild type), are shown in Fig. 3.
Low-confidence mutations and mutations detected using association rule mining. In 
addition to the detection of high-confidence mutations, whole genome sequences were used to search for 
low-confidence mutations as well as for unknown (combinations of) SNPs and indels or (combinations of) genes 
that were present/mutated more often in one of the resistant groups compared to the other groups. Previously 
Figure 2. Maximum likelihood trees of the WHO-TDR (a) and Bangladesh (b) isolates (rooted at the H37Rv 
reference genome). For each isolate, high-confidence mutations and lineage are depicted at the outside of the 
tree and along the corresponding branch, respectively.
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described low-confidence mutations were found in 58/129 WHO-TDR strains and 37/47 Bangladesh isolates 
(Supplementary Tables S1, S2 and S3). Newly found non-synonymous mutations in genes in which muta-
tions were described previously, were found in 95/129 WHO-TDR strains and 39/47 Bangladesh isolates 
Figure 3. Isoniazid MIC relative frequency distributions of isolates harbouring the inhA promoter region 
c-15t mutation alone, the katG Ser315Thr mutation alone, the combination of these two mutations, or no 
high-confidence mutation for isoniazid (wild type). WHO-TDR and Bangladesh isolates were pooled to allow 
comparison of low frequencies. WHO-TDR strains with an MIC up to and including 0.8 mg/L had this MIC 
determined previously. All other MICs were determined in this study, i.e. 1.6 mg/L was the lowest concentration 
used in this study. MIC = minimum inhibitory concentration.
susceptible 
(n = 58)
low-level resistance 
(n = 14)
moderate-level resistance 
(n = 88)
high-level resistance 
(n = 16)
n % n % n % n %
accD6 13 22.4% 4 28.6% 30 34.1% 7 43.8%
ahpC 0 0% 0 0% 1 1.1% 0 0%
efpA 1 1.7% 1 7.1% 1 1.1% 0 0%
fabD 2 3.4% 0 0% 4 4.5% 1 6.3%
fabG1 0 0% 0 0% 0 0% 1 6.3%
fadE24 3 5.2% 1 7.1% 13 14.8% 0 0%
fbpC 2 3.4% 0 0% 9 10.2% 2 12.5%
furA 1 1.7% 0 0% 0 0% 0 0%
inhA* 0 0% 0 0% 1 1.1% 0 0%
inhA promoter region* 0 0% 0 0% 4 4.5% 0 0%
iniA 7 12.1% 3 21.4% 13 14.8% 5 31.3%
iniB 1 1.7% 0 0% 3 3.4% 0 0%
iniC 1 1.7% 1 7.1% 2 2.3% 0 0%
kasA 2 3.4% 1 7.1% 6 6.8% 0 0%
katG* 2 3.4% 5 35.7% (p = 0.000) 9 10.2% 2 12.5%
katG Arg463Leu** 17 29.3% 4 28.6% 44 50.0% 11 68.8%
nat 1 1.7% 0 0% 5 5.7% 0 0%
ndh 1 1.7% 0 0% 1 1.1% 1 6.3%
oxyR’-ahpC intergenic region 3 5.2% 1 7.1% 11 12.5% 3 18.8%
Rv0340 1 1.7% 0 0% 11 12.5% 3 18.8%
Rv1592c 38 65.5% 8 57.1% 50 56.8% 13 81.3%
Rv1772 0 0% 0 0% 3 3.4% 0 0%
Rv2242 3 5.2% 0 0% 9 10.2% 2 12.5%
Table 2. Frequency of low-confidence mutations, both previously described low-confidence mutations3,30 and 
newly found mutations in genes in which mutations were described previously. Mutations were grouped by 
gene and WHO-TDR and Bangladesh isolates were pooled. Percentages given are based on the total number 
of isolates in each resistance group. *In this table only low-confidence mutations were included; **katG 
Arg463Leu has been reported as not associated with isoniazid resistance and is therefore shown in a separate 
row37,38; susceptible: MIC ≤ 0.2 mg/L; low-level resistance: 0.8 ≤ MIC ≤ 1.6 mg/L; moderate-level resistance: 
3.2 ≤ MIC ≤ 12.8 mg/L; high-level resistance: MIC ≥ 19.2 mg/L.
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(Supplementary Tables S1, S2 and S3). However, no mutations were associated with a particular MIC or resist-
ance level or explained the variation in isoniazid MICs of isolates with a katG Ser315Thr mutation. Grouping 
previously described and newly found low-confidence mutations by gene showed that mutations in Rv0340 
were significantly associated with high-level resistance (p = 0.008) and close to significantly associated with 
moderate-level resistance (p = 0.020) (Table 2). However, all phenotypically resistant isolates with a mutation in 
Rv0340 (n = 14) had high-confidence mutations as well, and all but one had an isoniazid MIC representative of 
the resistance level associated with these high-confidence mutations, which confounds the associations between 
Rv0340 mutations and resistance level. Previously described and newly found low-confidence mutations in katG 
were significantly associated with low-level isoniazid resistance (p = 0.000) (katG Arg463Leu was excluded from 
this calculation since it has been reported as not associated with isoniazid resistance)37,38 (Table 2). Among iso-
lates without high-confidence mutations, previously described low-confidence mutations were found in 1/6 
WHO-TDR strains (oxyR’-ahpC intergenic region c-52t) and 2/2 Bangladesh isolates (katG Arg463Leu, fbpC 
Gly158Ser, Rv2242 Met323Thr, inhA promoter region g-17t, and oxyR’-ahpC intergenic region g-88a in one isolate 
and oxyR’-ahpC intergenic region c-81t in the other isolate). However, these mutations were found in susceptible 
isolates as well (29.3% katG Arg463Leu, 3.4% fbpC Gly158Ser, and 3.4% Rv2242 Met323Thr) or occurred in only 
one isolate without high-confidence mutations (inhA promoter region g-17t, oxyR’-ahpC intergenic region c-52t, 
oxyR’-ahpC intergenic region c-81t, and oxyR’-ahpC intergenic region g-88a) (Supplementary Tables S1 and S2). 
Newly found low-confidence mutations in katG were found in 4/6 WHO-TDR strains without high-confidence 
mutations (all four were low-level resistant), along with other previously not described low-confidence mutations 
(Supplementary Tables S1). No unknown (combinations of) SNPs and indels (either grouped by gene or not) 
searched for with association rule mining were found to be reliably associated with one resistance group com-
pared to the other groups.
Discussion
This study, through the systematic linking of extensive isoniazid MIC data with genomic mutations, suggests that 
the combination of well-characterized, easily detectable mutations can reliably predict excessively high resistance 
of M. tuberculosis to isoniazid. We found that the combination of inhA promoter region and katG mutations is 
associated with the highest-level resistance (≥19.2 mg/L), exceeding peak level concentrations of the drug even 
at the highest doses in clinical use. Our results are largely in agreement with the associations between known 
resistance-conferring mutations and the level of phenotypic resistance described in the literature, typically tested 
at lower concentrations5–8. However, exceptions were not rare for single inhA promoter mutations, with some-
times not a low- but moderate-level MIC, similar to katG mutations. However, the mode of MICs associated with 
katG was at the upper limit of the peak isoniazid serum concentration at normal dosing (3–6 mg/L). In addition, 
the specificity of high-confidence mutations is high, as previously shown4.
Although previous research found that certain low-confidence mutations, e.g. in the oxyR’-ahpC intergenic 
region, contribute to the detection of phenotypically isoniazid-resistant isolates4, in this study, except for the 
association between low-confidence mutations in katG and low-level resistance, no overt association between 
low-confidence or unknown mutations and isoniazid resistance (level) was found. Although confounded by the 
association with high-confidence mutations, the association between mutations in Rv0340 and isoniazid resist-
ance found in this study calls for further investigation, especially given the fact that Rv0340 is located adjacent to 
the iniBAC operon, which has previously been found to play a potential role in isoniazid resistance3.
The analysis of low-confidence mutations was hampered by the relatively small sample size of our study, result-
ing in low frequencies of these mutations. Moreover, the selection criteria for the WHO-TDR and Bangladesh 
isolates have likely led to an overrepresentation of well-known resistance mutations and high levels of isoni-
azid resistance, respectively, which may limit the generalizability of our conclusion that a limited number of 
high-confidence mutations is able to predict the resistance level of the majority of isoniazid-resistant isolates.
Mutations in the promoter region of inhA were found by a previous study to not increase the risk of an unfa-
vourable treatment outcome (treatment failure or death) upon first-line treatment with 2 months of isoniazid, 
rifampicin, streptomycin and pyrazinamide, followed by 6 months of isoniazid and ethambutol, although such 
mutations did increase the risk of relapse13. In contrast, katG 315 mutations were associated with an unfavourable 
treatment outcome13. Whether katG mutations still predict an unfavourable treatment outcome upon treatment 
with higher doses of isoniazid, remains to be resolved. Since the majority of katG Ser315Thr MICs remains below 
the serum peak of around 15 mg/L upon the WHO recommended dose of 15–20 mg/kg19,39, isoniazid might still 
have a more or less important remaining activity when used in an otherwise effective regimen18,40. The high level 
of phenotypic resistance (≥19.2 mg/L) associated with the combination of katG Ser315Thr and the c-15t mutation 
in the inhA promoter region however exceeds this serum peak, making it highly unlikely that even high-dose 
isoniazid would still yield some clinical activity.
Dose-related side effects of isoniazid are a concern in patients taking higher doses. A study by Fox et al.40 dis-
cussing pharmacodynamics in patients in Madras, India, states that for isoniazid doses from 2.2 to 13.9 mg/kg, the 
AUC was most predictive of the incidence of peripheral neuropathy, while treatment outcome was best explained 
by peak serum concentrations and isoniazid resistance. In the Bangladesh cohort, neuropathy was infrequently 
seen in patients on double-dose isoniazid and was manageable by concurrent administration of pyridoxine. A 
randomised controlled trial by Katiyar et al.14 comparing high-dose isoniazid (16–18 mg/kg) to normal dose 
(5 mg/kg) or placebo found a significantly higher incidence of peripheral neuropathy in the group that received 
high-dose isoniazid compared to the other groups, but no higher incidence of hepatotoxicity.
The strong association between the combination of inhA c-15t and katG Ser315Thr and high-level resistance 
could be of importance for the interpretation of current and future molecular diagnostic tests, since rapid predic-
tion of the isoniazid resistance level is paramount for deciding whether to continue treatment with (high-dose) 
isoniazid or not. First-line LPAs like the Hain MTBDRplus can reliably identify isolates with these mutations and 
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thus predict the isoniazid resistance level too high to overcome, because of the combined katG and inhA promoter 
mutations found in our study, or reportedly also due to a katG deletion6,7. But contrary to widespread belief, an 
isolated katG or inhA mutation can indicate highly variable MIC levels. inhA mutations do not always indicate very 
low and katG mutations not necessarily very high resistance levels, so that first-line LPA cannot be used to decide 
with high confidence that isoniazid will or will not be useful in a combination regimen when only one of both is 
detected. Moreover, further research is required to investigate whether high-dose isoniazid indeed contributes to 
successful outcome in patients with low- or moderate-level resistance, caused by a katG or inhA mutation alone.
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